FDA advisory committee issues back to back negative votes on two cancer drugs
Spectrum Pharmaceuticals and Oncopeptides each received separate negative advisory committee votes for their respective cancer drugs. In other recent regulatory news, clinical trial holds were placed and lifted and the FDA is seeking public comment on its draft guidance for including children in clinical trials.
